Peter Hecht, Cyclerion Therapeutics CEO
April 3, 2023 11:03 AM EDTUpdated 11:21 AM
Deals

Sec­ond time’s the charm? Cy­cle­ri­on CEO tries again at buy­ing biotech's as­sets

Kyle LaHucik

Senior Reporter

As the re­serves run dry, Cy­cle­ri­on Ther­a­peu­tics is look­ing for a way to keep its drug de­vel­op­ment am­bi­tions alive, and the biotech’s board is giv­ing …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

WuXi AppTec will sell cell and gene ther­a­py busi­ness to pri­vate eq­ui­ty firm

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Ca­griSe­ma’s weight loss da­ta dis­ap­point­ed. What does No­vo do next?

Ver­tex gets 'van­za triple' ap­proval and Trikaf­ta ex­pan­sion — with boxed warn­ings

CMS ex­plains what went in­to its first round of drug price ne­go­ti­a­tions

PDU­FAs for Tonix and Nu­va­tion; Sanofi vac­cine part­ner­ship; RAPT al­ler­gy deal

A service from the Financial Times